Display options
Cite
Avnet S, Baldini N, Brisson L, et al. Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism. Front Oncol. 2018;8:329doi: 10.3389/fonc.2018.00329.
Avnet, S., Baldini, N., Brisson, L., De Milito, A., Otto, A. M., Pastoreková, S., Porporato, P. E., Szabadkai, G., & Sonveaux, P. (2018). Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism. Frontiers in oncology, 8329. https://doi.org/10.3389/fonc.2018.00329
Avnet, Sofia, et al. "Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism." Frontiers in oncology vol. 8 (2018): 329. doi: https://doi.org/10.3389/fonc.2018.00329
Avnet S, Baldini N, Brisson L, De Milito A, Otto AM, Pastoreková S, Porporato PE, Szabadkai G, Sonveaux P. Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism. Front Oncol. 2018 Oct 03;8:329. doi: 10.3389/fonc.2018.00329. eCollection 2018. PMID: 30338239; PMCID: PMC6179103.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2018 Oct 03;8:329. doi: 10.3389/fonc.2018.00329. eCollection 2018.

Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism.

Frontiers in oncology

Sofia Avnet, Nicola Baldini, Lucie Brisson, Angelo De Milito, Angela M Otto, Silvia Pastoreková, Paolo E Porporato, Gyorgy Szabadkai, Pierre Sonveaux

Affiliations

  1. Orthopaedic Pathophysiology and Regenerative Medicine Unit, Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy.
  2. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  3. INSERM UMR1069, Nutrition, Croissance et Cancer, Université François-Rabelais, Tours, France.
  4. Department of Oncology-Pathology, Karolinska Institute, and Sprint Bioscience, Stockholm, Sweden.
  5. Munich School of BioEngineering, Technical University of Munich, Munich, Germany.
  6. Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
  7. Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy.
  8. Department of Biomedical Sciences, University of Padua, Padua, Italy.
  9. Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom.
  10. The Francis Crick Institute, London, United Kingdom.
  11. Pole of Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.

PMID: 30338239 PMCID: PMC6179103 DOI: 10.3389/fonc.2018.00329

Abstract

Tumors are metabolic entities wherein cancer cells adapt their metabolism to their oncogenic agenda and microenvironmental influences. Metabolically different cancer cell subpopulations collaborate to optimize nutrient delivery with respect to immediate bioenergetic and biosynthetic needs. They can also metabolically exploit host cells. These metabolic networks are directly linked with cancer progression, treatment, resistance, and relapse. Conversely, metabolic alterations in cancer are exploited for anticancer therapy, imaging, and stratification for personalized treatments. These topics were addressed at the 4th annual meeting of the International Society of Cancer Metabolism (ISCaM) in Bertinoro, Italy, on 19-21 October 2017.

Keywords: cancer imaging; cancer therapy; proton dynamics; tumor metabolism; tumor microenvironment

References

  1. Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2715-26 - PubMed
  2. Front Pharmacol. 2017 Jul 04;8:411 - PubMed

Publication Types